List of Excipients in Branded Drug .INSULIN ASPART PROTAMINE AND INSULIN ASPART

« Back to Dashboard

Last updated: September 24, 2026

Insulin aspart protamine and insulin aspart is a premixed insulin product containing 70% intermediate-acting insulin aspart protamine suspension and 30% rapid-acting soluble insulin aspart. Its commercial opportunity is concentrated in biosimilar-like follow-on insulin, regional supply, device compatibility, stability, preservative systems, and lower-cost premix manufacturing rather than in novel excipient composition claims. The principal technical challenge is maintaining the suspension-to-solution ratio, resuspension behavior, potency, and pharmacokinetic profile across manufacturing scale-up and device presentations.

Insulin Aspart Protamine and Insulin Aspart: Excipient Strategy, Patent Position, and Commercial Opportunities

What is insulin aspart protamine and insulin aspart?

Insulin aspart protamine and insulin aspart is commonly known as insulin aspart 70/30. The product combines:

Component	Approximate proportion	Clinical role
Insulin aspart protamine suspension	70%	Intermediate-acting basal coverage
Soluble insulin aspart	30%	Rapid prandial coverage
Excipients and formulation agents	Product-specific	pH control, preservation, tonicity, zinc stabilization, and physical stability

The reference product in the United States is NovoLog Mix 70/30, marketed by Novo Nordisk. The product is supplied as a U-100 formulation and is administered by subcutaneous injection. The formulation is a suspension that must be resuspended before injection. The FDA label requires visual inspection and mixing or rolling according to the presentation instructions before use (U.S. Food and Drug Administration [FDA], 2023).

The product differs from premixed human insulin because it uses insulin aspart, a rapid-acting insulin analog, in both its soluble and protamine-complexed components. The formulation is designed to provide faster prandial action than conventional neutral protamine Hagedorn, or NPH, mixtures.

What excipients are used in insulin aspart 70/30?

The commercial formulation uses a conventional insulin excipient platform with a technically sensitive protamine suspension system.

Reported formulation components include:

Excipient or formulation component	Primary function
Protamine	Forms the intermediate-acting insulin aspart complex
Zinc	Supports insulin association and structural stability
Metacresol	Antimicrobial preservative and protein-stabilizing excipient
Phenol	Preservative and contributes to formulation stability
Glycerol	Tonicity adjustment
Disodium phosphate	Buffering and pH control
Sodium chloride	Tonicity and ionic-strength adjustment
Water for injection	Vehicle
Hydrochloric acid or sodium hydroxide	pH adjustment

The FDA labeling for NovoLog Mix 70/30 identifies glycerol, phenol, metacresol, zinc, disodium phosphate dihydrate, sodium chloride, and water among the formulation components. The label specifies a formulation pH generally maintained within approximately 7.1 to 7.5 (FDA, 2023).

Protamine is central to product performance. It is not a conventional inactive excipient in the commercial sense because it is combined with insulin aspart to create the active intermediate-acting fraction. A change in protamine concentration, molecular characteristics, mixing order, or complexation conditions can alter sedimentation, particle size, redispersibility, and insulin release.

How should an excipient strategy be designed for insulin aspart 70/30?

A successful excipient strategy must preserve five product attributes:

1. The 70:30 ratio between protamine-bound and soluble insulin aspart.
2. Rapid and reproducible resuspension after storage.
3. Dose uniformity throughout the vial, cartridge, or prefilled pen.
4. Chemical stability of insulin aspart during shelf life and in-use storage.
5. Comparable onset and duration of action to the reference product.

Protamine and zinc control

Protamine concentration is the most commercially important formulation variable. Excess protamine can increase the intermediate-acting fraction, slow release, and produce a longer absorption profile. Insufficient protamine can reduce suspension formation and shift the product toward rapid insulin exposure.

Zinc affects insulin association, crystal formation, and suspension morphology. Its concentration and ionic environment should be controlled with narrow process ranges. Zinc variability can produce changes in particle size and settling behavior even when total insulin potency remains within specification.

A development program should characterize:

• Protamine-to-insulin ratio.
• Zinc-to-insulin ratio.
• Particle-size distribution.
• Sedimentation rate.
• Resuspension time and number of inversions.
• Delivered-dose uniformity after storage.
• Free insulin and protamine-bound insulin fractions.
• Release profile in comparative pharmacology studies.

Preservative system

Metacresol and phenol provide antimicrobial protection in multidose containers and can affect insulin conformation, adsorption, and aggregation. Reducing preservative concentrations may create microbiological or stability risk. Increasing concentrations can create tolerability concerns and may change protein behavior.

Commercial developers should evaluate the preservative system in the final container closure system, not only in bulk solution. Adsorption to elastomeric stoppers, pen components, needles, and cartridge materials can change preservative availability during shelf life.

Buffer and tonicity

Phosphate concentration, sodium chloride, glycerol, and pH jointly influence protein solubility and suspension behavior. Glycerol is often preferable to higher ionic-strength systems when the product requires a balance between physiological tonicity and suspension stability.

A formulation platform should avoid unnecessary excipient changes because each change can trigger comparability work. The best commercial strategy is usually a reference-aligned formulation with targeted optimization of manufacturability, device compatibility, and in-use stability.

What formulations are protected by patents?

For insulin aspart 70/30, the principal defensible product characteristics historically have involved the insulin analog, protamine complex, formulation ratios, delivery systems, manufacturing processes, and specific methods of treatment.

Potential claim categories include:

Claim category	Typical protected subject matter	Commercial relevance
Active ingredient	Insulin aspart sequence and variants	Usually mature or expired for early products
Premix composition	Ratio of soluble insulin aspart to protamine-complexed insulin	May affect follow-on formulation design
Suspension formulation	Protamine, zinc, buffer, preservatives, and pH ranges	Can create formulation-specific barriers
Manufacturing process	Complexation, crystallization, mixing, filtration, and filling	May limit process copying
Delivery device	Pen, cartridge, dose selector, or compatibility features	Relevant to combination-product launches
Method of use	Dosing before meals, titration, or patient subgroup use	Usually narrower than composition claims
Stability and packaging	Container closure, storage, or in-use performance	Can support secondary patent positions

The core insulin aspart composition and early product patents are substantially mature. Patent risk therefore depends on the jurisdiction, specific dosage form, delivery device, manufacturing method, and any later-filed formulation or device patents. A product-by-product freedom-to-operate review must distinguish patents covering the active ingredient from patents covering the pen or presentation.

What is the Orange Book status of insulin aspart protamine and insulin aspart?

NovoLog Mix 70/30 is an FDA-approved insulin product associated with Novo Nordisk. The FDA Orange Book provides the relevant U.S. approval and patent-listing framework for approved drug products, but the regulatory pathway for follow-on insulin products is not identical to the conventional small-molecule ANDA model.

In the United States, insulin products transitioned from the Federal Food, Drug, and Cosmetic Act to the Public Health Service Act on March 23, 2020. Follow-on insulin products are generally regulated as biologics under the 351(a) or 351(k) pathway rather than through a traditional abbreviated new drug application. This transition affects interchangeability, exclusivity, patent certifications, and litigation procedure (FDA, 2020).

For insulin aspart 70/30, a commercial applicant must evaluate:

• The reference product’s biologic license and product presentation.
• Whether the proposed product qualifies as biosimilar or interchangeable.
• Device and presentation differences.
• Comparative analytical, pharmacokinetic, pharmacodynamic, and immunogenicity requirements.
• Any active patents listed for the reference product or associated delivery system.
• State substitution rules applicable to interchangeable biologics.

When does insulin aspart 70/30 lose exclusivity?

The core commercial exclusivity for early insulin aspart products has largely expired or matured. The key business question is no longer only whether the active ingredient is off patent. It is whether a competitor can obtain approval with a commercially acceptable presentation and demonstrate sufficient similarity in formulation performance and clinical use.

Exclusivity analysis should separate four layers:

Layer	Status assessment
Insulin aspart active ingredient	Mature product technology
Premixed 70/30 composition	Potential formulation and process claims require jurisdiction-specific review
Prefilled pen and cartridge	Device and combination-product claims may remain relevant
Manufacturing process	Trade secrets and process know-how may be more important than patents

No universal expiration date should be assigned to the entire product without a current patent-family and regulatory-record review. The product may have different expiration dates for composition, manufacturing, device, and method-of-use claims in different countries.

Are there Paragraph IV challenges for insulin aspart 70/30?

Traditional Paragraph IV litigation is less central after insulin products moved to the biologics framework. A conventional ANDA applicant certifies against listed patents under the Hatch-Waxman system. A biosimilar applicant instead operates under the Biologics Price Competition and Innovation Act patent-exchange and litigation framework.

For insulin aspart 70/30, potential disputes are more likely to involve:

• Biosimilar patent litigation.
• Interchangeability and substitution status.
• Device patents covering pens and cartridges.
• Manufacturing-process claims.
• Trade-secret disputes involving complexation and suspension production.
• Contract manufacturing or supply agreements.

The absence of a conventional Paragraph IV notice does not mean the product is free of patent risk. It means the relevant statutory route may be a biologics patent pathway rather than a traditional generic-drug challenge.

Which companies are challenging the insulin aspart 70/30 market?

The competitive field includes originator insulin manufacturers, biosimilar developers, regional insulin producers, contract manufacturers, and companies developing alternative delivery devices.

Relevant competitor categories include:

Competitor type	Strategic position
Novo Nordisk	Originator of NovoLog Mix 70/30 and NovoRapid Mix presentations
Eli Lilly	Competes through insulin lispro products, including premixed alternatives
Sanofi	Competes in insulin analogs and basal insulin, with a different premix position
Biocon Biologics	Has biosimilar insulin manufacturing and global commercialization capabilities
Wockhardt	Has insulin manufacturing and international market presence
Ypsomed and device suppliers	May influence pen and cartridge economics
Regional manufacturers	Can compete through lower-cost supply and local regulatory pathways

Competition is not limited to an identical insulin aspart 70/30 product. Insulin lispro 75/25, human insulin 70/30, basal-bolus therapy, and fixed-ratio injectable products can substitute for the same clinical need.

How strong is the patent estate for insulin aspart 70/30?

The patent estate is strongest around the formulation-process-device combination and weaker around the mature active ingredient.

Stronger protection areas

• Protamine complexation conditions.
• Particle-size and suspension-control processes.
• Specific pen or cartridge configurations.
• Container closure and in-use stability.
• Manufacturing controls that are difficult to reproduce without process know-how.
• Combination claims linking formulation and delivery device.

Weaker protection areas

• The general concept of insulin aspart.
• Conventional preservatives such as phenol and metacresol.
• Standard phosphate buffering.
• Glycerol-based tonicity adjustment.
• Broad insulin suspension concepts.

For investors and licensing teams, manufacturing know-how may be more valuable than a broad composition patent. Critical know-how includes raw-material specifications, protamine handling, zinc addition sequence, temperature control, mixing energy, hold times, filling conditions, and resuspension testing.

What manufacturing and IP barriers affect market entry?

The largest entry barriers are technical and regulatory rather than purely patent-based.

A follow-on manufacturer must establish:

• Consistent insulin aspart identity and potency.
• Controlled formation of the protamine-bound fraction.
• Stable suspension morphology.
• Comparable pharmacokinetics and pharmacodynamics.
• Low aggregation and degradation products.
• Robust aseptic filling.
• Compatibility with vials, cartridges, and pens.
• Acceptable in-use stability after repeated dosing.
• Reliable cold-chain distribution.

The product also creates supply-chain exposure to recombinant insulin drug substance, protamine, zinc salts, preservatives, elastomeric components, and specialized filling equipment. A manufacturer with a vertically integrated insulin platform has a cost advantage over a company that purchases drug substance and outsources complexation and filling.

What commercial opportunities exist for excipient suppliers?

Excipient suppliers can pursue several opportunities without developing a new insulin molecule.

High-value opportunities

1. Low-variability protamine systems.
   Pharmaceutical-grade protamine with tight molecular-weight, purity, and endotoxin specifications can reduce batch variability.

2. Insulin-compatible preservative systems.
   Suppliers can offer metacresol and phenol systems with validated protein-stability and container-closure performance.

3. Specialty zinc and buffer systems.
   High-purity zinc and phosphate systems can support reproducible crystal and suspension formation.

4. Device-compatible formulations.
   Excipient packages optimized for pen cartridges may improve dose delivery and reduce adsorption or clogging risk.

5. Longer in-use stability.
   Formulations that maintain potency and suspension uniformity after repeated temperature cycling have commercial value.

6. Regional manufacturing platforms.
   A standardized excipient and process package can support multiple insulin analog products across emerging markets.

The strongest commercial proposition is a formulation platform that reduces development time and manufacturing variability while remaining close enough to the reference product to limit regulatory risk.

How does insulin aspart 70/30 compare with competing premixed insulins?

Product class	Rapid component	Intermediate component	Commercial distinction
Insulin aspart 70/30	Insulin aspart	Insulin aspart protamine	Fast analog premix with established pen use
Insulin lispro 75/25	Insulin lispro	Insulin lispro protamine	Closest analog competitor
Human insulin 70/30	Regular human insulin	NPH insulin	Lower-cost, slower prandial profile
Basal-bolus therapy	Separate rapid and basal insulin	Separate basal insulin	Greater dosing flexibility, higher regimen complexity

Insulin aspart 70/30 competes on convenience and rapid prandial coverage. Human insulin premixes compete on price. Basal-bolus regimens compete on flexibility and titration control. A lower-cost follow-on product must therefore achieve more than regulatory approval. It must offer competitive pen pricing, payer access, pharmacy availability, and reliable supply.

What is the revenue exposure and generic launch risk?

Revenue exposure is highest in markets where the originator retains broad formulary access and where premixed insulin is widely prescribed. Risk rises when:

• A biosimilar or follow-on product secures interchangeability.
• Payers impose mandatory substitution.
• Public tenders prioritize price.
• Multiple manufacturers enter at the same time.
• The originator’s pen-device advantage weakens.
• Human insulin shortages or affordability pressures shift demand toward lower-cost alternatives.

A realistic launch sequence could involve a limited regional launch, hospital and tender channels, and vial or cartridge presentations before broad retail penetration. A fully integrated U-100 pen product requires greater capital but offers stronger differentiation than a vial-only product.

What is the outlook for formulation and licensing deals?

Licensing opportunities may involve:

• Regional rights to manufacture or commercialize insulin aspart 70/30.
• Supply agreements for insulin aspart drug substance.
• Contract development and manufacturing of protamine suspension products.
• Pen and cartridge technology.
• Interchangeable biologic development programs.
• Excipient and process packages for emerging-market insulin production.

A high-value deal would normally combine drug substance access, validated formulation know-how, analytical methods, regulatory support, and device compatibility. A license limited to excipients has less strategic value unless it includes proprietary suspension-control technology or differentiated stability data.

What litigation status should companies monitor?

Companies should monitor four litigation categories:

1. Biosimilar patent litigation under the BPCIA.
2. Device and combination-product patent disputes.
3. Manufacturing-process and trade-secret claims.
4. Contract disputes involving insulin supply, territorial rights, or minimum purchase commitments.

The practical litigation risk depends on the applicant’s proposed presentation. A vial-only product may avoid some pen claims but face weaker commercial adoption. A pen-based product may improve market access while increasing device-related patent exposure.

Key Takeaways

• Insulin aspart protamine and insulin aspart is a 70/30 premix containing 70% protamine-complexed insulin aspart and 30% soluble insulin aspart.
• Protamine, zinc, pH, preservatives, and mixing conditions control the product’s release profile and suspension quality.
• The commercial opportunity is strongest in follow-on biologics, regional manufacturing, tender supply, and device-compatible presentations.
• The active ingredient is technologically mature, but formulation, process, device, and manufacturing know-how can still create entry barriers.
• Traditional Paragraph IV analysis is less applicable after insulin products moved into the biologics framework.
• A successful competitor needs comparable pharmacology, robust resuspension behavior, a reliable cold chain, competitive device economics, and payer access.
• Excipient suppliers can create value through low-variability protamine, insulin-compatible preservative systems, zinc and buffer control, and improved in-use stability.

FAQs

What is the difference between insulin aspart and insulin aspart protamine?

Insulin aspart is the soluble rapid-acting component. Insulin aspart protamine is insulin aspart complexed with protamine to create a slower-absorbing intermediate-acting suspension.

Can insulin aspart 70/30 be reformulated without protamine?

A product without protamine would not be the same 70/30 premix. Removing protamine would materially change absorption, suspension behavior, dosing performance, and regulatory comparability.

Which excipient has the greatest impact on insulin aspart premix performance?

Protamine generally has the greatest impact because it determines formation and release of the intermediate-acting fraction. Zinc, pH, ionic strength, and mixing conditions also have major effects.

Is insulin aspart 70/30 a generic drug or a biosimilar?

In the United States, insulin products are regulated as biologics under the Public Health Service Act. A follow-on product is generally developed through a biosimilar or interchangeable biologic pathway rather than a conventional generic pathway.

What is the most defensible commercial differentiation for a follow-on product?

The strongest differentiation is usually a combination of lower cost, reliable pen or cartridge delivery, stable suspension performance, broader regional access, and validated manufacturing efficiency.

References

1. U.S. Food and Drug Administration. (2020). Insulin products and the transition to the biologics license application pathway. https://www.fda.gov/

2. U.S. Food and Drug Administration. (2023). NovoLog Mix 70/30 insulin aspart injectable suspension and insulin aspart injection prescribing information. Novo Nordisk A/S. https://www.accessdata.fda.gov/

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, commonly known as the Orange Book. https://www.fda.gov/

4. U.S. Food and Drug Administration. (2024). Biosimilar and interchangeable biosimilar products. https://www.fda.gov/

5. Novo Nordisk A/S. (2023). NovoLog Mix 70/30 product information. https://www.novolog.com/